Q-omics provides the consensus-scored MTCO2P19 profile across patient tissues and cancer cell-line models. MTCO2P19 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MTCO2P19 is differentially expressed in 2, with the highest sampling consensus in UCEC. Additionally, MTCO2P19 RNA expression shows 9,942 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, UCEC, and LSCC as cancer lineages where MTCO2P19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO2P19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO2P19 survival associations across molecular data types. MTCO2P19 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO2P19 RNA expression–survival associations across cancer types. High MTCO2P19 expression shows unfavorable associations in ACC and COAD, but favorable associations in OV, BLCA, UCS and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MTCO2P19 RNA expression.
This table summarizes MTCO2P19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in PAAD for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO2P19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO2P19 shows lower tumor expression in PAAD and higher tumor expression in UCEC. The UCEC box plot shows higher MTCO2P19 RNA expression in tumor versus normal tissue (log2 FC = +0.240, t-test p = .040).
This table shows molecular features associated with MTCO2P19 in patient tissues and cancer cell lines. In patient samples, MTCO2P19 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
